E84.0 Insurance Policy Changes

ICD-10 E84.0 is officially defined as "Cystic fibrosis with pulmonary manifestations." code E84.0 is referenced in 17 tracked payer policy changes from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E84.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jul 16, 2026High impact
Genetic Testing for Cystic Fibrosis 2.02.17
The July 16, 2026 update made expanded CFTR testing (CPT 81223) medically necessary when standard variant testing is insufficient to establish a diagnosis or assess reproductive risk, and when results will impact clinical or reproductive decision-making. Common-variant CF genetic testing is medically appropriate when results will impact clinical care, the test is performed by a CLIA-certified laboratory, and a listed circumstance applies, such as diagnostic testing for people with symptoms of CF and a negative sweat test, carrier testing for people with a family history of CF, or prenatal testing when both parents have a diagnosis of CF.
Blue Cross & Blue Shield of Mississippi · Effective Sep 1, 2025Medium impact
Cystic Fibrosis
Alyftrek (vanzacaftor, tezacaftor and deutivacaftor) is considered not medically necessary under this BCBSMS policy because there are other options covered by the Plan for cystic fibrosis. Kalydeco, Orkambi, Symdeko and Trikafta require prior authorization and are medically necessary for the listed age groups when the CFTR gene mutation is confirmed by genetic testing. The revision effective 09/01/2025 removed the CFTR gene mutation tables and revised the age, initial and renewal criteria, and the 05/26/2026 review left the policy statements unchanged.
Aetna · Identified Oct 29, 2026Medium impact
Noninvasive Tests for Hepatic Fibrosis (CPB 0690, reviewed 2026-10-26)
This Aetna Clinical Policy Bulletin (CPB 0690) addresses noninvasive tests for hepatic fibrosis and lists which tests Aetna considers medically necessary and which it considers experimental, investigational, or unproven. Aetna considers transient elastography (e.g., FibroScan) medically necessary for follow-up of primary sclerosing cholangitis, monitoring of liver function in Wilson's disease, and distinguishing hepatic cirrhosis from non-cirrhosis in persons with hepatitis B, hepatitis C or other chronic liver diseases. Performing transient elastography, magnetic resonance elastography, the Enhanced Liver Fibrosis (ELF) test, or FibroTest-ActiTest/HCV-FibroSure more than twice per year is considered not medically necessary.
Aetna · Identified Oct 6, 2026Medium impact
Lung Transplantation (CPB 0598, reviewed 2026-09-08)
Aetna considers lung transplantation medically necessary for qualifying conditions including cystic fibrosis, emphysema and alpha-1-antitrypsin deficiency, Eisenmenger's complex, primary pulmonary hypertension, pulmonary fibrosis, sarcoidosis, lymphangioleiomyomatosis with end-stage pulmonary disease, bronchopulmonary dysplasia, and graft-versus-host disease or failed primary lung graft, when the member meets the transplanting institution's selection criteria or, without those criteria, the general and disease-specific criteria in the policy. Cystic fibrosis requires at least 2 listed signs of clinical deterioration, such as decreasing FEV1, FEV1 less than 30% predicted, or recurrent massive hemoptysis, and emphysema requires both hospitalization for COPD exacerbation with hypercapnia in the preceding year and a BODE index of 7 or above. Lung transplantation is considered not medically necessary for malignancy involving the lung, multi-system disease, refractory uncontrolled hypertension, other effective treatments being available, and smoking without 6 months of abstinence.
Aetna · Identified Oct 4, 2026Medium impact
Home/Ambulatory Spirometry (CPB 0572, reviewed 2026-09-01)
Aetna's Clinical Policy Bulletin 0572 on home and ambulatory spirometry was last reviewed 09/01/2026. Aetna considers home spirometry and telespirometry medically necessary for lung transplant recipients, and experimental, investigational or unproven for asthma, cystic fibrosis, idiopathic pulmonary fibrosis, interstitial lung disease and other chronic pulmonary disorders such as emphysema. Spirometry Holter is also considered experimental, investigational or unproven for managing asthma, and CPT 94014, 94015 and 94016 and HCPCS E0487 are covered when selection criteria are met.
Aetna · Identified Oct 4, 2026Medium impact
Heart-Lung Transplantation (CPB 0597, reviewed 2026-09-08)
Aetna considers heart-lung transplantation medically necessary for persons with severe refractory heart failure plus either end-stage lung disease or irreversible pulmonary hypertension, when the selection criteria are met and no absolute contraindications are present. Examples of qualifying conditions include COPD with severe heart failure, cystic fibrosis with severe heart failure, congenital heart disease with pulmonary hypertension that is not amenable to lung transplantation and repair by standard cardiac surgery, and Eisenmenger's complex with irreversible pulmonary hypertension and severe heart failure. Heart-lung transplantation is considered not medically necessary where lung transplantation alone will restore right ventricular function.
Aetna · Identified Aug 18, 2026Medium impact
Total Body Plethysmography (CPB 0474, reviewed 2026-07-17)
Aetna's Clinical Policy Bulletin 0474 covers total body plethysmography as an adjunct to complete pulmonary function testing, including residual volumes and diffusion, for these indications: determining bronchial hyper-reactivity in response to methacholine, histamine, or isocapnic hyperventilation; determining response to bronchodilators in persons who show a clinical response but no FEV1 improvement by spirometry; evaluating obstructive lung diseases such as bullous emphysema and cystic fibrosis; evaluating airflow resistance in obstructive processes where plethysmography is needed for accurate true lung volumes; measuring lung volumes to distinguish restrictive from obstructive processes when vital capacity is below 80% predicted on spirometry; and measuring lung volumes when multiple repeated trials are required or the subject cannot perform multi-breath tests. The policy considers total body plethysmography experimental, investigational, or unproven for all other indications, including screening asymptomatic persons with chronic obstructive pulmonary disease, pectus excavatum, primary pulmonary hypertension, monitoring bleomycin toxicity, scoliosis, and systemic sclerosis.
Aetna · Identified Aug 18, 2026Medium impact
Nutritional Support (CPB 0061, reviewed 2026-01-15)
Aetna considers nutritional support a medical item only when it is given by feeding tube or intravenously to a member with permanent non-function or disease of the structures that normally permit food to reach the small bowel, or with small bowel disease that impairs digestion and absorption of an oral diet, and when adequate nutrition cannot be met by dietary adjustment or oral supplements. Aetna does not cover nutritional support taken orally unless state law mandates it, and it does not cover banked breast milk, food supplements, specialized infant formulas, or vitamins and minerals taken orally. Parenteral nutrition is considered medically necessary when adequate intake is not possible by oral or tube feeding, such as after documented enteral failure, when the gastrointestinal tract must be totally non-functioning for a period of time, or when structural or functional bowel disease makes oral and tube feedings inappropriate.
Aetna · Identified Aug 18, 2026Medium impact
Iontophoresis (CPB 0229, reviewed 2026-04-23)
Aetna considers iontophoresis medically necessary for delivering local anesthetic before emergent skin puncture or dermatological procedures, for intractable disabling primary focal hyperhidrosis of the axillae, palms or soles when the stated criteria are met, for short-term iontophoretic fentanyl for acute postoperative pain, and for the sweat test by pilocarpine iontophoresis to diagnose cystic fibrosis. The policy lists many other uses as experimental, investigational or unproven, including acetic acid for rotator cuff disease, heel pain and epicondylitis, corticosteroid or NSAID iontophoresis for musculoskeletal disorders, onychomycosis and tinnitus, because of insufficient evidence of its effectiveness. CPT 97033 is covered for iontophoresis only when the selection criteria are met.
Aetna · Identified Aug 18, 2026Medium impact
Home/Ambulatory Spirometry (CPB 0572, reviewed 2025-08-26)
Aetna considers home spirometry and telespirometry medically necessary for lung transplant recipients. It considers them experimental, investigational or unproven for asthma, cystic fibrosis, idiopathic pulmonary fibrosis, interstitial lung disease and other chronic pulmonary diseases such as emphysema. CPT 94014, 94015 and 94016 and HCPCS E0487 are covered only if the selection criteria are met.
Aetna · Identified Aug 17, 2026Medium impact
Heart-Lung Transplantation (CPB 0597, reviewed 2025-12-02)
Aetna considers heart-lung transplantation medically necessary for persons with severe refractory heart failure plus either end-stage lung disease or irreversible pulmonary hypertension, when the selection criteria are met and no absolute contraindications are present. Heart-lung transplantation is considered not medically necessary where lung transplantation alone will restore right ventricular function, and every attempt should be made to preserve the heart. The member must meet the transplanting institution's selection criteria, and in the absence of those criteria, Aetna's listed criteria apply.
Aetna · Identified Aug 17, 2026Medium impact
Genetic Counseling (CPB 0189, reviewed 2026-03-27)
Aetna considers genetic counseling medically necessary for listed pregnancy-related indications, including couples who are closely related genetically, familial cancer disorders, pregnant women with maternal age 35 years or greater at delivery, and parents of a child born with a genetic disorder or birth defect. Genetic counseling unrelated to pregnancy is covered when it is appropriate for, or provided with, medically necessary genetic testing in accordance with ACMG guidelines. Genetic counseling for all other indications is considered experimental, investigational or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Nebulizers (CPB 0065, reviewed 2026-03-18)
Aetna covers small volume nebulizers and related compressors for listed indications, including antibiotics for cystic fibrosis or bronchiectasis, beta-adrenergics and other inhaled drugs for COPD, dornase alfa for cystic fibrosis or primary ciliary dyskinesia, and epinephrine for croup. Large volume nebulizers are considered medically necessary for pentamidine, bronchiectasis, cystic fibrosis, tracheobronchial stents, and tracheostomy, and ultrasonic nebulizers are considered medically necessary only for tobramycin (Tobi) delivery in members with cystic fibrosis who meet the criteria for a standard nebulizer and the additional criteria in the policy. Aetna considers these nebulizers and related equipment experimental, investigational, or unproven for all other indications, including nebulized corticosteroids for nasal polyps and viral wheezing, nebulized lidocaine, and nebulized magnesium for pediatric asthma.
Aetna · Identified Aug 13, 2026Medium impact
Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)
Aetna considers palivizumab (Synagis) medically necessary for commercial medical plans for up to 5 doses per RSV season to prevent serious lower respiratory tract disease caused by RSV, when a member has a qualifying diagnosis such as prematurity, chronic lung disease of prematurity, hemodynamically significant congenital heart disease, cystic fibrosis or profound immunocompromise and the associated criteria are met. Palivizumab is excluded for members who have received nirsevimab-alip (Beyfortus) in the same RSV season. The American Academy of Pediatrics stated that in July 2025 it no longer routinely recommends using Synagis.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions
High-frequency chest wall compression devices and intrapulmonary percussive ventilation devices may be considered medically necessary in individuals with cystic fibrosis or chronic diffuse bronchiectasis when standard chest physical therapy has failed or is unavailable or not tolerated. An oscillatory positive expiratory pressure device may be considered medically necessary in individuals with hypersecretory lung disease who have difficulty clearing secretions and recurrent disease exacerbations. Other applications, including use as an adjunct to chest physical therapy and use in chronic obstructive pulmonary disease or respiratory conditions associated with neuromuscular disorders, are considered investigational.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Lung and Lobar Lung Transplant
Lung transplantation may be considered medically necessary for carefully selected individuals with irreversible, progressively disabling, end-stage pulmonary disease unresponsive to maximum medical therapy. A lobar lung transplant from a living or deceased donor may be considered medically necessary for carefully selected individuals with end-stage pulmonary disease, including conditions such as bilateral bronchiectasis, alpha-1 antitrypsin deficiency, and cystic fibrosis (both lungs to be transplanted). Lung or lobar retransplantation after a failed transplant may be considered medically necessary for individuals who meet criteria, and all other situations are investigational.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Heart/Lung Transplant
Heart/lung transplantation is considered medically necessary for carefully selected individuals with end-stage cardiac and pulmonary disease, including irreversible primary pulmonary hypertension with heart failure, cystic fibrosis with severe heart failure, emphysema with severe heart failure, and pulmonary fibrosis with uncontrollable pulmonary hypertension or heart failure. Heart/lung retransplantation after a failed primary heart/lung transplant may be considered medically necessary for individuals who meet the criteria for heart/lung transplantation. Heart/lung transplantation in all other situations is considered investigational.

Watch E84.0

Get one email when a payer policy names E84.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E84.0?

There are 17 tracked policy changes affecting code E84.0, including updates from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E84.0?

Payers that have issued tracked updates for code E84.0 include: Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code E84.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E84.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E84.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Genetic Testing for Cystic Fibrosis 2.02.17

Cystic Fibrosis

Noninvasive Tests for Hepatic Fibrosis (CPB 0690, reviewed 2026-10-26)

Lung Transplantation (CPB 0598, reviewed 2026-09-08)

Home/Ambulatory Spirometry (CPB 0572, reviewed 2026-09-01)

Heart-Lung Transplantation (CPB 0597, reviewed 2026-09-08)

Total Body Plethysmography (CPB 0474, reviewed 2026-07-17)

Nutritional Support (CPB 0061, reviewed 2026-01-15)

Iontophoresis (CPB 0229, reviewed 2026-04-23)

Home/Ambulatory Spirometry (CPB 0572, reviewed 2025-08-26)

Heart-Lung Transplantation (CPB 0597, reviewed 2025-12-02)

Genetic Counseling (CPB 0189, reviewed 2026-03-27)

Nebulizers (CPB 0065, reviewed 2026-03-18)

Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions

Lung and Lobar Lung Transplant

Heart/Lung Transplant

What insurance policy changes affect code E84.0?

Which payers have updated policy for code E84.0?

How do I get notified when code E84.0 policy changes?

Why do payers change policies for code E84.0?